Current disease status-First occurrence of the cancer Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the cancer Posts on Medivizor

Evaluating the effectiveness and safety of cemiplimab plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer.

Evaluating the effectiveness and safety of cemiplimab plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer.

Posted by on Mar 5, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of cemiplimab (Libtayo) plus chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that cemiplimab plus chemotherapy as first-line treatment was effective with manageable side effects in these patients. Some...

Read More

Evaluating the role of radiotherapy in HER2+ early-stage breast cancer after breast-conserving surgery

Evaluating the role of radiotherapy in HER2+ early-stage breast cancer after breast-conserving surgery

Posted by on Mar 5, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the effectiveness of radiotherapy (RT) in patients with HER2+ early-stage breast cancer (BC) after breast-conserving surgery (BCS). The study found that RT improved the survival rates of these patients, especially for those high-risk. Some background BC is categorized based on the absence or...

Read More

Evaluating the effectiveness and safety of mFOLFOXIRI chemotherapy with or without radiotherapy before surgery in patients with locally advanced rectal cancer

Evaluating the effectiveness and safety of mFOLFOXIRI chemotherapy with or without radiotherapy before surgery in patients with locally advanced rectal cancer

Posted by on Jan 26, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safery of administering modified (m) FOLFOXIRI (folinic acid, fluorouracil, irinotecan, oxaliplatin) chemotherapy with or without radiotherapy before surgery in patients with locally advanced rectal cancer (LARC). The results showed that this treatment was safe and improved survival without disease...

Read More

Comparing the frequency and severity of nerve disease with eribulin versus paclitaxel before surgery in women with breast cancer

Comparing the frequency and severity of nerve disease with eribulin versus paclitaxel before surgery in women with breast cancer

Posted by on Jan 15, 2023 in Breast cancer | 0 comments

In a nutshell The study compared the frequency and severity of neuropathy (nerve damage) eribulin (Halaven) with paclitaxel (Taxol) given before surgery in women with operable breast cancer (BC). The study found that the frequency and severity of neuropathy were reduced in patients who received eribulin than in patients who received...

Read More

Evaluating the safety and effectiveness of FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of metastatic colorectal cancer

Evaluating the safety and effectiveness of FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of metastatic colorectal cancer

Posted by on Jan 8, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab (Avastin) with or without atezolizumab (Tecentriq) on the outcomes of patients with metastatic (m) colorectal cancer (CRC). The study showed that adding atezolizumab to FOLFOXIRI plus...

Read More

Evaluating the effectiveness and safety of transanal versus laparoscopic total mesorectal resection for the treatment of patients with rectal cancer.

Evaluating the effectiveness and safety of transanal versus laparoscopic total mesorectal resection for the treatment of patients with rectal cancer.

Posted by on Jan 8, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of transanal (ta) versus laparoscopic (lap) total mesorectal resection (TME) for the treatment of patients with stage I-III rectal cancer (RC). The data showed that experienced surgeons can safely perform taTME in these patients. Some background Rectal cancer (RC) is one of the most...

Read More

Evaluating the effectiveness of transanal endoscopic microsurgery for the treatment of early rectal cancer in patients over 60 years old with high surgical risk.

Evaluating the effectiveness of transanal endoscopic microsurgery for the treatment of early rectal cancer in patients over 60 years old with high surgical risk.

Posted by on Jan 3, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness of transanal endoscopic microsurgery (TEM) for the treatment of early rectal cancer (RC) in patients over 60 years old with high surgical risk. The data showed that TEM is a reliable and effective treatment option in high-risk patients over 60 years old. Some background Rectal cancer (RC) is one of...

Read More

Evaluating the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected NSCLC.

Evaluating the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected NSCLC.

Posted by on Jan 3, 2023 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of different platinum-based chemotherapy regimens given after surgery for the treatment of early-stage resected non-small cell lung cancer (NSCLC). The authors concluded that the combination of cisplatin (Platinol)-vinorelbine (Nevelbine) improved the outcomes of these patients. Also, the...

Read More

Evaluating the effect of total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy and planned adjuvant chemotherapy on the survival of patients with locally advanced rectal cancer.

Evaluating the effect of total neoadjuvant therapy versus standard neoadjuvant chemoradiotherapy and planned adjuvant chemotherapy on the survival of patients with locally advanced rectal cancer.

Posted by on Sep 1, 2022 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effect of total neoadjuvant therapy (TNT) versus standard neoadjuvant chemoradiotherapy (CRT) and planned adjuvant chemotherapy on the survival of patients with locally advanced rectal cancer (LARC). The data showed that TNT did not increase survival compared with standard CRT and planned adjuvant...

Read More

Adding pembrolizumab before and after surgery for early triple-negative breast cancer

Adding pembrolizumab before and after surgery for early triple-negative breast cancer

Posted by on Jun 30, 2022 in Breast cancer | 0 comments

In a nutshell This study aimed to investigate pembrolizumab (Keytruda) before and after surgery in patients with early triple-negative breast cancer (TNBC).  This study concluded that the addition of pembrolizumab to chemotherapy before surgery and after surgery for TNBC improved the survival without complications from TNBC in these...

Read More

Is chemotherapy after surgery followed by atezolizumab a good treatment option in patients with early stage non-small-cell lung cancer?

Is chemotherapy after surgery followed by atezolizumab a good treatment option in patients with early stage non-small-cell lung cancer?

Posted by on Feb 7, 2022 in Lung cancer | 0 comments

In a nutshell The study aimed to investigate the effectiveness and safety of atezolizumab (Tecentriq) versus best supportive care after chemotherapy in patients with resected early-stage non-small-cell lung cancer (NSCLC). The study showed atezolizumab is effective and has better outcomes than best supportive in these...

Read More

Can osimertinib be used as first-line therapy in older patients with EGFR-mutated NSCLC?

Can osimertinib be used as first-line therapy in older patients with EGFR-mutated NSCLC?

Posted by on Jan 30, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of osimertinib (Tagrisso) as first-line therapy for older patients above 75 years with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). The data showed that osimertinib as first-line therapy is effective in these patients. However, osimertinib was...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2023 Medivizor